当前位置:首页 - 行情中心 - 双鹭药业(002038) - 财务分析 - 利润表

双鹭药业

(002038)

  

流通市值:63.98亿  总市值:77.15亿
流通股本:8.52亿   总股本:10.27亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入304,859,306.03168,896,131.59660,419,604.31540,562,431.05
  营业收入304,859,306.03168,896,131.59660,419,604.31540,562,431.05
二、营业总成本290,269,767.12155,955,363.45621,412,318.94461,951,501.39
  营业成本113,612,947.3968,792,328.23211,533,255.13170,782,084.55
  税金及附加3,346,179.64741,836.697,785,648.985,073,775.28
  销售费用45,723,204.7619,904,477.41117,181,775.591,222,553.23
  管理费用78,105,521.2338,850,701.09142,731,340.59101,968,231.45
  研发费用52,662,971.3928,942,931.49149,623,443.0398,929,930.35
  财务费用-3,181,057.29-1,276,911.46-7,443,144.29-6,025,073.47
  其中:利息收入2,640,398.331,315,341.568,396,576.286,565,621.23
三、其他经营收益
  加:公允价值变动收益110,052,337.2125,524,228.94-172,293,877.63-121,662,443.96
  加:投资收益10,278,335.25,591,921.6713,127,545.1318,516,475.89
  资产处置收益403.03--1,142.29
  资产减值损失(新)---556,697.75-
  信用减值损失(新)-378,150.19282,246.51-11,092,825.48-13,442,742.02
  其他收益4,884,714.444,006,991.4512,205,218.385,661,293.9
四、营业利润139,427,178.648,346,156.71-119,603,351.98-32,315,344.24
  加:营业外收入1.660.2370,826.981.12
  减:营业外支出3,166,977.46323,03614,217,127.644,851,464.01
五、利润总额136,260,202.848,023,120.94-133,749,652.64-37,166,807.13
  减:所得税费用15,637,333.742,405,937.61-58,462,889.66-19,420,932.88
六、净利润120,622,869.0645,617,183.33-75,286,762.98-17,745,874.25
(一)按经营持续性分类
  持续经营净利润120,622,869.0645,617,183.33-75,286,762.98-17,745,874.25
(二)按所有权归属分类
  归属于母公司股东的净利润121,048,202.745,968,405.62-74,065,657.76-16,735,581.13
  少数股东损益-425,333.64-351,222.29-1,221,105.22-1,010,293.12
  扣除非经常损益后的净利润26,004,427.8221,141,816.582,336,980.0177,990,657.18
七、每股收益
  (一)基本每股收益0.120.04-0.07-0.02
  (二)稀释每股收益0.120.04-0.07-0.02
九、综合收益总额120,622,869.0645,617,183.33-75,286,762.98-17,745,874.25
  归属于母公司股东的综合收益总额121,048,202.745,968,405.62-74,065,657.76-16,735,581.13
  归属于少数股东的综合收益总额-425,333.64-351,222.29-1,221,105.22-1,010,293.12
公告日期2025-08-262025-04-222025-04-222024-10-26
审计意见(境内)标准无保留意见
TOP↑